BID: A Drug Target and Potential Therapeutic Target in Diseases

Target Name: BID

NCBI ID: G637

Content of Review Report on BID Target / Biomarker

BID

BID: A Drug Target and Potential Therapeutic Target in Diseases

BID (B菒n D菒) is a drug target (also known as a biomarker) that has been identified and characterized in the scientific literature. BID is a protein that is expressed in various tissues and cells of the human body, including the brain, heart, and blood vessels. It is involved in the regulation of cell proliferation, apoptosis (programmed cell death), and angiogenesis (the formation of new blood vessels). BID has been shown to play a key role in the development and progression of several diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

The Identification and Characterization of BID

BID was first identified in the late 1990s by researchers at the University of California, San Diego. They used a combination of genetic, cellular, and biochemical techniques to demonstrate that BID is a unique and highly conserved protein that is expressed in various tissues and cells of the human body. Since then, numerous studies have confirmed the validity of this identification and further characterized the protein.

The Structure and Mechanism of BID

BID is a member of the TGF-β (transforming growth factor-尾) family of proteins. This family is known for their ability to promote cell proliferation, differentiation, and survival. BID is characterized by a unique N-terminus that contains a conserved domain called TGRE (TGF-β receptor interacting) and a C-terminus that contains a catalytic domain and a unique structural motif called KIM (Kirsten) domains.

The TGRE domain is known for its ability to interact with the TGF-β receptor, which is a key regulator of cell proliferation and survival. The KIM domains are involved in the regulation of protein-protein interactions and in the regulation of cellular processes such as cell adhesion, migration, and invasion.

The Mechanism of BID

BID is involved in the regulation of cell proliferation, apoptosis, and angiogenesis. It has been shown that BID plays a key role in the regulation of cell proliferation by promoting the G1 checkpoint, which is a critical step in the G1/S transition that occurs during the regulation of cell growth.

In addition to its role in cell proliferation, BID is also involved in the regulation of apoptosis. Apoptosis is a natural and necessary process for the elimination of damaged or dysfunctional cells in the body. BID has been shown to promote apoptosis in various cell types, including cancer cells, neurons, and heart muscle cells.

Furthermore, BID is involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed in the body. BID has been shown to promote the formation of new blood vessels in various tissues, including the skin, the gut, and the brain.

Disease Relevance

BID is involved in the development and progression of several diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

In cancer, BID has been shown to promote the growth and survival of various cancer cell types. For example, studies have shown that BID can promote the growth of breast cancer cells, increase their survival, and resistance to chemotherapy.

In neurodegenerative diseases, BID has been shown to contribute to the progression of neurodegeneration. For example, studies have shown that BID can promote the development of neurofibrillary tangles and the progression of neurodegeneration in various neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In cardiovascular diseases, BID has been shown to contribute to the development and progression of various cardiovascular diseases. For example, studies have shown that BID can promote the formation of new blood vessels in the heart and contribute to the development of heart failure.

Conclusion

In conclusion, BID is a protein that is involved in the regulation of cell proliferation, apoptosis, and angiogenesis. It has been

Protein Name: BH3 Interacting Domain Death Agonist

Functions: Induces caspases and apoptosis (PubMed:14583606). Counters the protective effect of BCL2 (By similarity)

The "BID Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BID comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets